PRNB News and Press, Principia Biopharma Inc. From 02/19/20

In our original report on Principia Biopharma, we emphasized that BTK inhibitors have failed over and over in autoimmune diseases, which we attribute to a basic problem with their mechanism of action: their main effect is to impair the production of new B-cell lineages, leaving the previou...

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today announced that management will participate in the SVB Leerink Global ...

We are short shares of Principia Biopharma ( PRNB ). Last week, Sanofi, the large pharma company that has licensed Principia’s BTK inhibitor SAR442168 for use in multiple sclerosis, announced that the drug met the primary endpoint of its Phase 2 trial. In our original report on Prin...

Sanofi (NASDAQ: SNY ) perks up  3%  premarket on light volume in reaction to positive results from a Phase 2b clinical trial evaluating SAR442168 in patients with relapsing multiple sclerosis (MS). More news on: Sanofi, Principia Biopharma Inc., Healthcare stocks news, Stocks...

Healthcare Pulse The market doesn't like uncertainty. And when you think about healthcare, that uncertainty is immediately magnified. Fundamentally, healthcare couldn't be better positioned, with an aging America, rapidly advancing therapies, a faster-moving FDA, easy access to risk capi...

Tonix Pharmaceuticals (TNXP) reported favorable results for the tests on its lead drug candidate TNX 102 SL. The pharma company had conducted fed-fasting and dose proportionality tests of the drug candidate in healthy volunteers. The data will be used to support a New Drug Application for trea...

This article was highlighted for PRO+ subscribers, Seeking Alpha’s service for professional investors. Find out how you can get the best content on Seeking Alpha here . We are short shares of Principia Biopharma (NASDAQ: PRNB ), a company whose $2 billion valuation rests on a sing...

Source: GraycellAdvisors.com Systematic Investing Systematic investing has become a growing part of the stock market. The investing style refers to a rules-based algorithmic system that limits or eliminates individual judgments and biases towards portfolio selection and adjustments. ...

Principia Biopharma’s (Nasdaq: PRNB ) stock gained more than 50% from our previous assessment. It was mostly driven by rumors about possible buyout from big pharma and hype among BTK inhibitors after Merck’s (Nasdaq: MRK ) $ 2.7 billion bid for AqQule for their lead canc...

Company expands focus on immune-mediated diseases and  suspends FGFR program Company outlines anticipated key corporate milestones SOUTH SAN FRANCISCO, Calif., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company foc...